%0 Journal Article
%T Divergences in Antiviral Therapy for Diabetic Patients with COVID-19
%A Andreea Fitero
%A Nicoleta Negruț
%A Delia Carmen Nistor Cseppento
%A Delia Mirela Tit
%A Paul Andrei Negru
%A Cristian Bustea
%A Andrei Flavius Radu
%A Simona Gabriela Bungau
%J Pharmacophore
%@ 2229-5402
%D 2024
%V 15
%N 2
%R 10.51847/pERPVY0am7
%P 79-89
%X Patients with diabetes are particularly susceptible to COVID-19 infection, which can result in severe respiratory illness. This study conducted a comparative assessment of the impact of antiviral therapy using molnupiravir and favipiravir in COVID-19 patients with underlying diabetes. A cohort of one hundred individuals infected with SARS-CoV-2, diagnosed with diabetes, and consecutively admitted, was included in the present study. These patients were treated with antivirals according to local guidelines: Group F (51 cases) was treated with favipiravir – 10 days and Group M (49 cases) was treated with molnupiravir – 5 days. In Group F, the average hospitalization was higher than in Group M (11.29±2.27 vs. 7.14±3.16, p
%U https://pharmacophorejournal.com/article/divergences-in-antiviral-therapy-for-diabetic-patients-with-covid-19-1kxm8zqmkjmhayt